A Phase 4 interventional study of Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol in Contraception, sponsored by Ortho-McNeil Janssen Scientific Affairs, LLC. Completed. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-19.
Sponsored by Ortho-McNeil Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Hemorrhage by Johnson & Johnson — 1 open to participants now, 1 under way, none of them phase 3. Hemorrhage · Johnson & Johnson.
Among the 16 studies in Hemorrhage by Johnson & Johnson, this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2008, is one of 3 in phase 4, and was the 3rd registered.
1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.
Browse Hemorrhage studies →1 of the 16 studies in Hemorrhage by Johnson & Johnson is open now. Recruiting first, the newest first:
Ethicon Endo-Surgery
Ages 18+
Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 355 is above the median of 102 across 927 interventional studies indexed under Hemorrhage.
Median enrollment 150 across the 13 interventional studies, 488 across the 3 observational. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Ortho-McNeil Janssen Scientific Affairs, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Ortho-McNeil Janssen Scientific Affairs, LLC is the lead sponsor of 16 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Hemorrhage by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study in healthy sexually active females is to evaluate the cycle control with norgestimate/ethinyl estradiol versus drospirenone/ethinyl estradiol.
This is a randomized, open-label, active-controlled, multicenter study in healthy sexually active females to evaluate cycle control with norgestimate/ethinyl estradiol versus drospireneone/ethinyl estradiol. The Open-Label Treatment Phase will last for three 28-day cycles. Approximately 300 patients will be randomized in a 1:1 fashion according to a predetermined randomization schedule. Patients will be seen for a baseline visit (Visit 1) up to 35 days prior to dosing to obtain informed consent, have a physical examination including a breast exam, height and weight, vital signs, a Chlamydia test and a urine pregnancy test performed, and to give their medical history. Patients will be instructed to report bleeding data using an interactive voice response system (IVRS) based diary on a daily basis. Patients will be instructed to continue taking 1 pill each day for 3 cycles, record this information daily in the IVRS and to contact the study site if they have any questions or adverse events they would like to discuss. The final study visit (Visit 2) will occur on Day 8 after completing 3 cycles of study medication. Patients will be weighed, have vital signs performed, report any adverse events and or changes in concomitant medications, and complete the satisfaction questionnaire at the final visit. Safety will be assessed by physical examinations, adverse events, body weight and vital signs. Patients randomized to drospireneone/ethinyl estradiol and taking any medication that could increase serum potassium levels (as outlined in the Package Insert) will also have their potassium level checked during their first cycle of treatment (Days 15 to 28 of treatment). Three 28-day cycles of either norgestimate/ethinyl estradiol or drospirenone/ethinyl estradiol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug pages: Norgestimate · Ethinyl Estradiol · Drospirenone
Number of Days of Unscheduled Blood Loss - Cycle 1
cycle control between treatment groups, cycle 1. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.
Time frame: Cycle 1 (Day 8 to 21 for NGM/25mcg EE and day 8 to 24 for DRSP/20mcg EE)
Number of Days of Unscheduled Blood Loss - Cycle 2
cycle control between treatment groups, cycle 2. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.
Time frame: Cycle 2 (Day 29 to 49 for NGM/25mcg EE and day 29 to 52 for DRSP/20mcg EE)
Number of Days of Unscheduled Blood Loss - Cycle 3
Number of Days of Unscheduled Blood Loss - Cycle 3. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.
Time frame: Cycle 3 (Day 57 to 77 for NGM/25mcg EE and day 57 to 80 for DRSP/20mcg EE)
Overall Number of Days of Unscheduled Blood Loss
cycle control between treatment groups, for three 28-day cycles. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.
Time frame: Cycle 1 to Cycle 3 (Day 8 to Day 80)
Number of Participants With the Indicated Number of Unscheduled Blood Loss Episodes
Unscheduled blood loss episodes are bounded on both sides by at least 1 non- bleeding day.
Time frame: Cycle 1 to Cycle 3 (Day 8 to Day 80)
Number of Days of Scheduled Blood Loss - Cycle 1
cycle control between treatment groups, cycle 1. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen.
Time frame: Cycle 1 (Day 22 to 32 for NGM/25mcg EE and day 25 to 32 for DRSP/20mcg EE)
Number of Days of Scheduled Blood Loss - Cycle 2
cycle control between treatment groups, cycle 2. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen.
Time frame: Cycle 2 (Day 50 to 60 for NGM/25mcg EE and day 53 to 60 for DRSP/20mcg EE)
Number of Days of Scheduled Blood Loss - Cycle 3
cycle control between treatment groups, cycle 3. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen.
Time frame: Cycle 3 (Day 78 to 84 for NGM/25mcg EE and day 81 to 84 for DRSP/20mcg EE)
Overall Number of Days of Scheduled Blood Loss
summary of the overall number of days of scheduled blood loss. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen.
Time frame: Cycle 1 to Cycle 3 (Day 8 to Day 84)
Number of Days of Total Blood Loss - Cycle 1
cycle control between treatment groups, cycle 1. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity.
Time frame: Cycle 1 (Day 8 to Day 28)
Number of Days of Total Blood Loss - Cycle 2
cycle control between treatment groups, cycle 2. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity.
Time frame: Cycle 2 (day 29 to Day 56)
Number of Days of Total Blood Loss - Cycle 3
cycle control between treatment groups, cycle 3. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity.
Time frame: Cycle 3 (Day 57 to Day 84)
Overall Number of Days of Total Blood Loss
cycle control between treatment groups, overall. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity.
Time frame: Cycle 1 to 3 (Day 8 to Day 84)
Number of Participants With Unscheduled Bleeding Cycle 1
Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.
Time frame: Cycle 1 (Day 8 to 21 for NGM/25mcg EE and day 8 to 24 for DRSP/20mcg EE)
Number of Participants With Unscheduled Bleeding Cycle 2
Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.
Time frame: Cycle 2 (Day 29 to 49 for NGM/25mcg EE and day 29 to 52 for DRSP/20mcg EE)
Number of Participants With Unscheduled Bleeding Cycle 3
Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.
Time frame: Cycle 3 (Day 57 to 77 for NGM/25mcg EE and day 57 to 80 for DRSP/20mcg EE)
Number of Participants With Breakthrough Bleeding/Spotting Cycle 1
Breakthrough bleeding/spotting is any bleeding or spotting during active pills excluding days contiguous with withdrawal bleeding or continual withdrawal bleeding.
Time frame: Cycle 1 (Day 8 to 21 for NGM/25mcg EE and day 8 to 24 for DRSP/20mcg EE)
Number of Participants With Breakthrough Bleeding/Spotting Cycle 2
Breakthrough bleeding/spotting is any bleeding or spotting during active pills excluding days contiguous with withdrawal bleeding or continual withdrawal bleeding.
Time frame: Cycle 2 (Day 29 to 49 for NGM/25mcg EE and day 29 to 52 for DRSP/20mcg EE)
Number of Participants With Breakthrough Bleeding/Spotting Cycle 3
Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.
Time frame: Cycle 3 (Day 57 to 77 for NGM/25mcg EE and day 57 to 80 for DRSP/20mcg EE)
Patient Satisfaction - Overall
patient satisfaction based on 5 questions during three 28-day cycles - Question 1 (Overall Satisfaction). On a scale of 1 to 5 where 1=Very satisfied and 5=Very dissatisfied.
Time frame: Cycle 1 to Cycle 3
| Milestone | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Started | 178 | 177 |
| Completed | 154 | 156 |
| Not completed | 24 | 21 |
| Withdrew: Adverse event | 3 | 4 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Lost to follow-up | 7 | 4 |
| Withdrew: Pregnancy | 2 | 4 |
| Withdrew: Lack of compliance | 2 | 2 |
| Withdrew: Patient's next menses did not start with | 1 | 0 |
| Withdrew: Results of pap smear at vis 1 malignant | 0 | 2 |
| Withdrew: Chlamydia test at visit 1 was positive | 1 | 1 |
| Withdrew: Patient didn't take any study medication | 7 | 3 |
cycle control between treatment groups, cycle 1. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.
| Days | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Number of Days of Unscheduled Blood Loss - Cycle 1 | 1.9 ± 3.14 | 2.0 ± 3.53 |
patient satisfaction based on 5 questions during three 28-day cycles - Question 1 (Overall Satisfaction). On a scale of 1 to 5 where 1=Very satisfied and 5=Very dissatisfied.
| Participants | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Number of responses | 159 | 162 |
| 1. Very Satisfied | 99 | 115 |
| 2. Somewhat satisfied | 35 | 32 |
| 3. Neither satisfied or dissatisfied | 12 | 6 |
| 4. Dissatisfied | 11 | 8 |
| 5. Very dissatisfied | 2 | 1 |
cycle control between treatment groups, cycle 2. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.
| Days | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Number of Days of Unscheduled Blood Loss - Cycle 2 | 1.3 ± 2.49 | 1.9 ± 2.86 |
Number of Days of Unscheduled Blood Loss - Cycle 3. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.
| Days | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Number of Days of Unscheduled Blood Loss - Cycle 3 | 1.4 ± 2.33 | 2.4 ± 2.86 |
cycle control between treatment groups, for three 28-day cycles. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.
| Days | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Overall Number of Days of Unscheduled Blood Loss | 4.6 ± 5.33 | 6.1 ± 6.07 |
Unscheduled blood loss episodes are bounded on both sides by at least 1 non- bleeding day.
| Participants | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| 0 Episode | 55 | 29 |
| 1 Episode | 46 | 41 |
| 2 Episodes | 23 | 50 |
| 3 Episodes | 21 | 22 |
| 4 Episodes | 13 | 11 |
| 5 Episodes | 7 | 8 |
| 6 Episodes | 0 | 2 |
| 8 Episodes | 0 | 3 |
| 9 Episodes | 0 | 1 |
cycle control between treatment groups, cycle 1. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen.
| Days | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Number of Days of Scheduled Blood Loss - Cycle 1 | 4.3 ± 2.09 | 3.2 ± 2.35 |
cycle control between treatment groups, cycle 2. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen.
| Days | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Number of Days of Scheduled Blood Loss - Cycle 2 | 4.0 ± 2.15 | 2.8 ± 2.40 |
cycle control between treatment groups, cycle 3. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen.
| Days | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Number of Days of Scheduled Blood Loss - Cycle 3 | 3.1 ± 2.09 | 1.2 ± 1.30 |
summary of the overall number of days of scheduled blood loss. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen.
| Days | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Overall Number of Days of Scheduled Blood Loss | 11.2 ± 5.40 | 7.0 ± 4.80 |
cycle control between treatment groups, cycle 1. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity.
| Days | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Number of Days of Total Blood Loss - Cycle 1 | 6.2 ± 3.88 | 5.2 ± 4.45 |
cycle control between treatment groups, cycle 2. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity.
| Days | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Number of Days of Total Blood Loss - Cycle 2 | 5.3 ± 2.66 | 4.6 ± 3.25 |
cycle control between treatment groups, cycle 3. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity.
| Days | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Number of Days of Total Blood Loss - Cycle 3 | 4.6 ± 2.64 | 3.6 ± 3.10 |
cycle control between treatment groups, overall. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity.
| Days | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Overall Number of Days of Total Blood Loss | 15.8 ± 6.58 | 13.2 ± 6.90 |
Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.
| Participants | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Number of Participants With Unscheduled Bleeding Cycle 1 | 72 | 74 |
Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.
| Participants | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Number of Participants With Unscheduled Bleeding Cycle 2 | 57 | 87 |
Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.
| Participants | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Number of Participants With Unscheduled Bleeding Cycle 3 | 65 | 94 |
Breakthrough bleeding/spotting is any bleeding or spotting during active pills excluding days contiguous with withdrawal bleeding or continual withdrawal bleeding.
| Participants | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Number of Participants With Breakthrough Bleeding/Spotting Cycle 1 | 53 | 56 |
Breakthrough bleeding/spotting is any bleeding or spotting during active pills excluding days contiguous with withdrawal bleeding or continual withdrawal bleeding.
| Participants | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Number of Participants With Breakthrough Bleeding/Spotting Cycle 2 | 39 | 62 |
Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.
| Participants | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Number of Participants With Breakthrough Bleeding/Spotting Cycle 3 | 47 | 74 |
Collected over 35 days prior to the first day study drug was taken to study day 91 (or 7 days after last day of study drug). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NGM/25mcg EE | — | 2/167 (1.2%) | 34/167 (20.4%) |
| DRSP/20mcg EE | — | 1/167 (0.6%) | 34/167 (20.4%) |
| Event | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/167 | 0/167 |
| Ovarian cyst rupturedReproductive system and breast disorders | 1/167 | 0/167 |
| Pelvic hemorrhageReproductive system and breast disorders | 1/167 | 0/167 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/167 | 1/167 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/167 | 0/167 |
| Event | NGM/25mcg EE | DRSP/20mcg EE |
|---|---|---|
| Mood swingsPsychiatric disorders | 3/167 | 5/167 |
| IrritabilityGeneral disorders | 1/167 | 4/167 |
| NauseaGastrointestinal disorders | 4/167 | 1/167 |
| AcneSkin and subcutaneous tissue disorders | 0/167 | 3/167 |
| Pharyngitis streptococcalInfections and infestations | 3/167 | 0/167 |
| SinusitisInfections and infestations | 3/167 | 0/167 |
| Back painMusculoskeletal and connective tissue disorders | 1/167 | 2/167 |
| Breast tendernessReproductive system and breast disorders | 2/167 | 0/167 |
| DysmenorrheaReproductive system and breast disorders | 0/167 | 2/167 |
| HeadacheNervous system disorders | 2/167 | 2/167 |
| Age, Customized(participants) | NGM/25mcg EE | DRSP/20mcg EE | Total |
|---|---|---|---|
| <18 years | 0 | 0 | 0 |
| >= 18 and < 65 years | 178 | 177 | 355 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | NGM/25mcg EE | DRSP/20mcg EE | Total |
|---|---|---|---|
| Mean | 27.2 ± 6.70 | 27.2 ± 6.52 | 27.2 ± 6.60 |
| Sex: Female, Male(Participants) | NGM/25mcg EE | DRSP/20mcg EE | Total |
|---|---|---|---|
| Female | 178 | 177 | 355 |
| Male | 0 | 0 | 0 |
No study locations are listed for this record.
The record gives a start of May 2008, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2010, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Norgestimate · Ethinyl Estradiol · Drospirenone
Ortho-McNeil Janssen Scientific Affairs, LLC →